A structured, risk-mitigated operational architecture tailored for the complex lifecycle of specialized and hormonal therapeutics. Engineered to support applicable regulatory, cold-chain, and clinical governance requirements.
Transparency as a Standard of Governance
At EndoCare+, we hold that operational excellence in high-consequence therapies must be demonstrable, verifiable, and systematically governed. Publishing our operational framework provides our global manufacturing partners and healthcare institutions with complete visibility into our risk-mitigation protocols. This outline reflects our commitment to cold-chain integrity, regulatory coordination, and proactive pharmacovigilance—supporting patient safety and continuous product availability at every stage.
No product enters active inventory without documented Quality Assurance (QA) release and complete thermal-logger audit verification.
Dossier maintenance, lifecycle compliance, and commercial logistics execute concurrently to support market access without compromising regulatory rigor.
EndoCare+ maintains a mandate to suspend distribution immediately at any node in the supply chain upon detection of pharmacovigilance or quality signals.
Therapeutic Portfolio Mapping, Bilateral Due Diligence, and Operational Readiness
Conducting comprehensive epidemiological and clinical assessments within the endocrinology, fertility, and metabolic sectors. We define precise Target Product Profiles (TPPs) for essential therapies—such as Somatropin, Gonadotropins, and Thyroid replacements—to directly address local healthcare gaps and institutional demands.
Aligning portfolio selection with validated clinical needs ensures that imported therapies provide immediate, high-value solutions to specialists and patients.
Identifying and shortlisting qualified global pharmaceutical manufacturers possessing specialized biological production capabilities, verified applicable GMP compliance, and demonstrated supply stability. Initial engagements assess strategic alignment and long-term portfolio synergy.
Executing formal Non-Disclosure Agreements (NDAs) to establish a legal framework for secure data exchange. We conduct joint economic modeling, analyzing pricing structures, market accessibility, and volume forecasts to ensure commercial sustainability for all stakeholders.
Executing a comprehensive mutual evaluation. EndoCare+ assesses the supplier's global regulatory standing and technical capabilities, while presenting full audit access to our local Good Distribution Practice (GDP) aligned infrastructure, thermal storage facilities, and compliance track record.
Multi-directional due diligence supports regulatory bodies' oversight of supply chain integrity while confirming our operational capacity to applicable standards.
Is clinical demand validated, legal confidentiality secured, commercial viability established, and mutual due diligence approved?
Proceed to Phase 2 (Commercial Contracting & Technical Verification)
Suspend engagement; re-evaluate therapeutic parameters or archive partnership profile.
CTD Dossier Evaluation, Binding Agreements, and Quality Technical Standards
Conducting a collaborative regulatory gap analysis utilizing standard Dossier Summaries (e.g., Quality Overall Summary - QOS) and regulatory checklists. We align the manufacturer's CTD documentation with local SBDMA clearance requirements and Bioequivalence (BE) compliance, supporting a smooth registration pathway prior to commercial execution.
Aligning regulatory expectations early supports both parties' resource investments and facilitates overall time-to-market without compromising clinical safety standards.
Executing binding exclusive agency agreements following successful dossier verification. Terms formally establish international Incoterms, Minimum Order Quantities (MOQs), supply lead times, and locked pricing structures designed to preserve long-term market stability and product availability.
Establishing an independent Quality Technical Agreement (QTA) that explicitly defines the matrix of shared operational responsibilities. The QTA legally binds both parties to cold-chain storage standards, thermal transport protocols, deviation handling mechanisms, and batch recall workflows.
Auditing packaging components, labeling, and patient leaflets. We ensure the integration of serialized 2D Data Matrix barcodes, localized language requirements, Braille accessibility, and clear thermal storage indicators in alignment with applicable SBDMA regulations prior to submission.
Are technical dossiers fully validated, commercial agreements executed, QTA established, and packaging artwork approved?
Proceed to Phase 3 (Dual-Track Regulatory Enablement)
Initiate Dossier Gap Analysis with manufacturer or re-negotiate terms.
Formal Dossier Submission, Statutory Import Authorization, and Lifecycle Compliance
Harmonizing and filing the primary Common Technical Document (eCTD/CTD Format) with the Supreme Board of Drugs and Medical Appliances (SBDMA) to initiate formal product evaluation for permanent Marketing Authorization (MA).
Activating legal, expedited importation mechanisms—such as SBDMA Special Import Permits or institutional emergency access provisions—to fulfill critical, unmet clinical demands for high-priority therapies while formal dossier registration is actively under review.
Emergency import protocols are executed strictly under statutory regulatory frameworks for urgent public health requirements, ensuring essential therapies reach specialized centers without bypassing compliance standards.
Coordinating official dossier evaluation with SBDMA technical committees, facilitating official laboratory sample testing and verification, addressing regulatory queries, and securing final Marketing Authorization approval.
Maintaining continuous regulatory oversight to manage post-approval variations, manufacturing updates, stability reporting, and timely registration renewals across the product's lifespan.
Is the product authorized for import via formal Marketing Authorization OR a validated SBDMA Special Import Permit?
Proceed to Phase 4 (Cold-Chain Logistics, Expedited Customs & QA Release)
Resolve regulatory queries or hold shipment until standard registration approval.
End-to-End Thermal Governance, Air & Sea Port Protocols, and QA Release
Issuing formal Shipping Authorization after verifying transport modes (Air Freight or Sea Reefer Containers). We validate reefer container pre-cooling parameters (2°C – 8°C), verify flight/vessel schedules, and calibrate multi-sensor electronic data loggers to minimize holding delays at ports of entry.
Monitoring thermal stability throughout international transit. For air freight, data loggers track ambient and internal cargo temperatures. For sea freight, we enforce continuous power plug-in protocols at transshipment ports and verify reefer container data-logging systems continuously.
Executing pre-cleared customs protocols immediately upon arrival. Air cargo is transferred directly from aircraft cold holds into refrigerated vehicles, while sea reefer containers maintain continuous power plug-in at port terminals during expedited customs inspection to prevent thermal degradation.
Time-Out-of-Refrigeration (TOR) is a critical quality attribute in biological logistics. Pre-arrival documentation clearance protects cold-chain continuity across both airport tarmacs and seaport terminals.
Transporting shipments from ports of entry via controlled refrigerated vehicle fleets equipped with dual-cooling systems to central storage facilities. Cargo is directly received into Good Distribution Practice (GDP) aligned cold storage quarantine rooms (2°C – 8°C).
Extracting and analyzing raw data from calibrated data loggers and reefer container temperature records. Quality Assurance teams map full temperature profiles against stability data to verify that no Mean Kinetic Temperature (MKT) or absolute limit excursions occurred during transit.
Coordinating official sampling with the SBDMA National Quality Control Laboratory while performing internal batch inspection. Upon receiving compliant statutory certificates of analysis (CoAs) and completing QA documentation review, stock is formally released from quarantine to active FEFO inventory.
Did the multimodal shipment pass continuous thermal logger audits, physical integrity checks, and statutory laboratory analysis?
Proceed to Phase 5 (Targeted Scientific Launch & Specialist Channel Distribution)
Maintain Quarantine. Initiate formal Deviation Investigation & CAPA protocol with manufacturer and shipping lines. Execute batch disposition or replacement protocols.
Scientific Engagement, Specialist Channel Qualification, and Cold-Chain Last-Mile Logistics
Auditing and qualifying target healthcare channels—including reference hospitals, fertility centers, and specialized pharmacy networks—to verify their local cold-chain storage infrastructure, emergency backup power systems, and handling capabilities before authorizing product dispatch.
Supporting healthcare advancement by sponsoring accredited Continuous Medical Education (CME) programs, hosting specialized scientific symposia, and participating in national endocrinology and fertility congresses. We facilitate peer-to-peer clinical exchanges to keep specialists updated on evolving therapeutic protocols.
All educational sponsorships and congress participation strictly adhere to applicable codes of ethical pharmaceutical promotion, ensuring complete independence of clinical judgment.
Facilitating formal product evaluation processes for inclusion in reference hospital drug formularies, clinical protocols, and specialized public/private sector procurement networks with defined delivery schedules.
Managing warehouse storage and order dispatch through automated First-Expired-First-Out (FEFO) inventory controls. Products are distributed via dedicated temperature-monitored refrigerated fleets, supporting continuous thermal preservation until final delivery to hospitals and pharmacies.
Activating a dedicated Medical Information Service to address clinical inquiries from specialists, provide guidance on product handling and reconstitution protocols, and ensure continuous professional support for prescribing physicians.
Are healthcare channels qualified, scientific engagement active, hospital formularies integrated, and cold-chain last-mile delivery operational?
Proceed to Phase 6 (Post-Market Surveillance, PV & Supply Continuity)
Re-evaluate channel thermal compliance, address medical information queries, or recalibrate distribution routes.
Statutory PV Compliance, Product Lifecycle Governance, and Supply Chain Resilience
Operating a dedicated Pharmacovigilance (PV) function to collect, triage, and evaluate Adverse Drug Reactions (ADRs) and Individual Case Safety Reports (ICSRs). We utilize official national reporting forms provided by the Supreme Board of Drugs and Medical Appliances (SBDMA) National PV Center, alongside international standard templates (CIOMS / ICH E2B). Periodic Safety Update Reports (PSURs/PBRERs) are systematically submitted to SBDMA and global partners.
Harmonizing SBDMA statutory reporting frameworks with international CIOMS standards supports national compliance while feeding safety data directly into global pharmacovigilance networks.
Systematically processing Technical Product Complaints (TPCs), packaging defects, and suspected sub-standard or counterfeit products. Our QA and PV teams execute immediate root-cause investigations in direct coordination with the manufacturer's Quality Unit, escalating findings to SBDMA as mandated by national vigilance guidelines.
Enforcing digital unit tracking via serialized 2D Data Matrix barcodes across warehousing, transit, and point-of-dispensing nodes. This infrastructure maintains real-time channel visibility, allowing rapid batch isolation down to the single box level within minutes.
Executing simulated, unannounced Mock Recalls at least annually to benchmark organizational readiness. Upon detection of a critical safety or quality defect, EndoCare+ executes rapid batch withdrawal protocols within 24 hours, operating in direct coordination with SBDMA enforcement teams and healthcare centers.
Demonstrating a validated, sub-24-hour mock recall protocol reflects our operational commitment to protecting patient health and maintaining regulatory trust.
Utilizing predictive analytics to monitor consumption rates and dynamic lead times for highly sensitive biologicals. We establish and maintain statutory safety stock reserves to prevent therapeutic stockouts, insulating hospitals and specialized clinics against international supply chain disruptions.
Are pharmacovigilance signals safe, quality complaints resolved, batch traceability validated, and buffer stocks maintained?
Maintain Standard Operations & Replenishment Cycle
Activate Batch Containment / Rapid Recall Protocol. Notify SBDMA immediately and initiate joint CAPA workflow.
EndoCare+ operates in cooperation with Sabrah Pharma within the broader Sabrah pharmaceutical platform. By combining Sabrah Pharma’s regulatory heritage and cold-chain infrastructure with our targeted clinical focus, we support appropriate supply resilience, institutional trust, and market continuity across all operational nodes.
The strategic roadmap outlined on this page represents our macro-level governance framework. Operationally, every step across all six phases is executed through a comprehensive library of Standard Operating Procedures (SOPs). These detailed SOPs enforce micro-level compliance, strict validation checklists, and standard deviation workflows aligned with applicable WHO-GDP principles, SBDMA statutory mandates, and relevant international guidelines.
We provide dedicated channels for healthcare professionals and patients to report safety concerns or review our quality commitments: